About Zybio
Zybio is a publicly listed company. Animal vaccines for swine, poultry, cattle, and pets are manufactured. It operates on a Direct-to-Consumer (D2C) and Reseller / Distribution model. The company has 277 employees. Zybio offers products and services including Swine Vaccines, Poultry Vaccines, Cattle and Sheep Vaccines, and Pet Vaccines. Its focus areas include Biotechnology and Animal Health. Its legal entity in India is Jilin Zybio Biological Products Co., Ltd (U99999MH1977PLC010754).
Company details
Animal vaccines are manufactured by Zybio, focusing on swine, poultry, cattle, sheep, and pets. Operations are based in Jilin City, China, with 14 GMP production lines. Products are exported to countries like Egypt, Pakistan, and Vietnam. Innovation is emphasized through research centers and laboratories for vaccine development. Recognition as a high-tech enterprise and multiple awards for industry contributions are received. The sector of animal health is primarily served with a focus on quality and technological advancement.
- Employees 277
- Stage Public
- SectorsHealthcare
- Website jlzybio.com
- Legal Name Zhengye Biotechnology Holding Limited
- Annual Revenue$16.19 M (USD)-37.49as on Dec 31, 2025
- Net Profit-$9.71 M (USD)-717.68as on Dec 31, 2025
- EBITDA-$6.2 M (USD)-210.55as on Dec 31, 2025
- Employee Count277
Associated legal entities of Zybio
Zybio operates through , (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| , CIN U99999MH1977PLC010754 | Active | 10 Aug 1977 | Nanded, Maharashtra | View details |
Products & Services of Zybio
Zybio offers a comprehensive portfolio of products and services, including Swine Vaccines, Poultry Vaccines, Cattle and Sheep Vaccines, and Pet Vaccines.
Vaccines for swine are developed to prevent diseases.
Vaccines for poultry are produced to ensure protection.
Vaccines for cattle and sheep prevent specific diseases.
Vaccines for pets are designed for disease prevention.
IPO & Listings of Zybio
Zybio is a publicly listed company on the NASDAQ with ticker symbol ZYBT in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date07 Jan 2025
- Listed onNASDAQ: ZYBT
- Listed entityZhengye Biotechnology Holding Limited
- Exchange sectorHealth technology
- ISINKYG989MS1016
- Share price$1.48 (-12.43% on the day) · 2026-10-13
- Market capitalisation$44.0M
- Volume (last session)430,126
Financials of Zybio
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $16.2M | -$9.7M | -$6.2M |
| 2024 | $25.9M | $1.6M | $5.6M |
| 2023 | $29.9M | $4.4M | $11.1M |
| 2022 | $38.6M | $6.9M | $12.7M |
| 2021 | $33.2M | $6.0M | $10.8M |
Balance sheet, profit and loss, cash flow and ratios of , are on its company page.
Detailed financial statements for Zybio
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Web traffic of Zybio
The website of Zybio (jlzybio.com) receives about 1K visits a month.
- Monthly visits1K
▲ 5% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Zybio
Complete news archive for Zybio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Zybio
Zybio has 277 employees.
Annual revenue of Zybio is $16.19M as on Dec 31, 2025.
Animal vaccines are manufactured by Zybio, focusing on swine, poultry, cattle, sheep, and pets. Operations are based in Jilin City, China, with 14 GMP production lines. Products are exported to countries like Egypt, Pakistan, and Vietnam. Innovation is emphasized through research centers and laboratories for vaccine development. Recognition as a high-tech enterprise and multiple awards for industry contributions are received. The sector of animal health is primarily served with a focus on quality and technological advancement.
Zybio offers Swine Vaccines, Poultry Vaccines, Cattle and Sheep Vaccines, and Pet Vaccines.
Yes, Zybio is publicly traded on NASDAQ under the ticker symbol ZYBT.
Zybio operates through ,.

